The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.
The scientific priorities of the ACTG network include research to:
- Identify strategies to cure and/or achieve a functional cure for HIV
- Improve the diagnosis and treatment of tuberculosis, especially in those co-infected with HIV
- Identify strategies to cure infectious hepatitis
- Prevent or improve the treatment of, non-infectious co-morbidities and evaluate novel interventions targeting HIV Infection
- Improve the treatment for viral related malignancies in HIV-infected adults
Main Areas of Focus
- To cure HIV infection
- To reduce the burden of disease due to HIV infection and its complications, including tuberculosis and viral hepatitis
The Executive Committee provides oversight and resource allocation through its Scientific Agenda Steering Committee. The Transformative and Collaborative Science Groups, with input from and integration with the Resource Committees and the other committees, are empowered to develop, implement, and monitor the scientific agenda of the ACTG.
The ACTG has conducted more than 100 studies since 2006. These studies have led to more than 400 peer-reviewed publications. The results of some of these studies have been used to make changes to HIV/AIDS treatment guidelines.
From time to time, the ACTG publishes requests for application (RFA) from investigators to address special research questions that are of high priority to the network. In addition, the RFA may solicit applications to add additional non-Division of AIDS (DAIDS) funded Clinical Research Sites to a study if it is determined that they are needed to meet the required sample size.
The ACTG includes clinical research sites around the world.